COMMUNIQUÉS West-GlobeNewswire

Aphaia Pharma Completes Enrollment in Arm 2 of Phase 2 Trial in Individuals with Obesity
13/06/2024
Enrollment has been completed for the last four cohorts evaluating the contribution of circadian effects in weight loss treatment using Aphaia’s formulation Topline data anticipated in Q3 and Q4 2024 for Arm 1 and Arm 2 [...]
Sharps Technology Receives $30 Million Purchase Order for Prefillable Copolymer Syringes to be Manufactured at SC Facility
13/06/2024
Signed PO secures first 12 months of syringe product orders against Sharps and Nephron’s five-year, $200 million Syringe Sales Agreement. Current Asset Purchase Agreement closing timeline is on track for expected [...]
Replimune Announces $100 Million Private Placement Financing
13/06/2024
- Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors - - Financing follows strong primary analysis data from [...]
Intelligent Bio Solutions Implements Strategic Reorganization Plan to Support Global Growth Initiatives
13/06/2024
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]
TOMI Environmental Solutions Supports Partners and Customers to Combat Global Avian Influenza (H5N1) Bird Flu Outbreak
13/06/2024
FREDERICK, Md., June 13, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization [...]
Opus Genetics Announces $1.7 Million in Project-based Funding from the Foundation Fighting Blindness to Support Two Preclinical Programs
13/06/2024
$1M TRAP award to support preclinical safety study for gene therapy vector targeting rhodopsin- RHO-adRP Additional project and operational funding to support MERTK gene therapy IND-enabling studies RESEARCH TRIANGLE [...]
Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling
13/06/2024
- First landmark, peer-reviewed publication of successful in vivo CAR T-cell data in an immune competent NHP model - - Data validate the VivoVec™ platform in a translationally relevant model and support its transition [...]
Dentsply Sirona Provides Update on June Investor Conference Participation
12/06/2024
CHARLOTTE, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that it is canceling its participation in the Goldman Sachs 45th Annual Global [...]
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
12/06/2024
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
Cellectis dévoile une approche de thérapie génique non-virale pour traiter la drépanocytose dans Nature Communications
12/06/2024
NEW YORK, 12 juin 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN ® pour développer [...]
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
12/06/2024
Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transition Experienced life [...]
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
12/06/2024
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand [...]
NANOBIOTIX ORGANISE UNE DISCUSSION VIRTUELLE ENTRE EXPERTS SUR LE POTENTIEL DE NBTXR3 EN IMMUNOTHÉRAPIE DANS LE CANCER DE LA TÊTE ET DU COU ET D’AUTRES INDICATIONS LE 18 JUIN 2024
12/06/2024
PARIS et CAMBRIDGE, Mass., 12 juin 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société » ), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to sustainable growth
12/06/2024
ESG commitments recognized as strategic business investments bringing value to stakeholders, including customers and employees // Environment: 15% reduction in Scope 1 and 2 emissions in 2023 through green energy [...]
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/06/2024
SOUTH SAN FRANCISCO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on June 10, 2024, it granted stock options to purchase an aggregate of 120,000 shares of [...]
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
12/06/2024
NOVATO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and [...]
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
12/06/2024
– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June 12, 2024 (GLOBE [...]
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
12/06/2024
The development of VTP-300 in chronic Hepatitis B (CHB) and VTP-1000 in celiac disease will be prioritized. The pipeline prioritization is expected to result in a reduction in workforce of approximately 25% and an [...]
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
12/06/2024
BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines [...]

Pages